Different Mutagenic Potential of HIV-1 Restriction Factors APOBEC3G and APOBEC3F is Determined by Distinct Single-stranded DNA Scanning Mechanisms

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2014 Mar 22

PMID 24651717

Citations 38

Authors

Anjuman Ara

Robin P Love

Linda Chelico

Affiliations

Soon will be listed here.

Abstract

The APOBEC3 deoxycytidine deaminase family functions as host restriction factors that can block replication of Vif (virus infectivity factor) deficient HIV-1 virions to differing degrees by deaminating cytosines to uracils in single-stranded (-)HIV-1 DNA. Upon replication of the (-)DNA to (+)DNA, the HIV-1 reverse transcriptase incorporates adenines opposite the uracils, thereby inducing C/G→T/A mutations that can functionally inactivate HIV-1. Although both APOBEC3F and APOBEC3G are expressed in cell types HIV-1 infects and are suppressed by Vif, there has been no prior biochemical analysis of APOBEC3F, in contrast to APOBEC3G. Using synthetic DNA substrates, we characterized APOBEC3F and found that similar to APOBEC3G; it is a processive enzyme and can deaminate at least two cytosines in a single enzyme-substrate encounter. However, APOBEC3F scanning movement is distinct from APOBEC3G, and relies on jumping rather than both jumping and sliding. APOBEC3F jumping movements were also different from APOBEC3G. The lack of sliding movement from APOBEC3F is due to an ¹⁹⁰NPM¹⁹² motif, since insertion of this motif into APOBEC3G decreases its sliding movements. The APOBEC3G NPM mutant induced significantly less mutations in comparison to wild-type APOBEC3G in an in vitro model HIV-1 replication assay and single-cycle infectivity assay, indicating that differences in DNA scanning were relevant to restriction of HIV-1. Conversely, mutation of the APOBEC3F ¹⁹¹Pro to ¹⁹¹Gly enables APOBEC3F sliding movements to occur. Although APOBEC3F ¹⁹⁰NGM¹⁹² could slide, the enzyme did not induce more mutagenesis than wild-type APOBEC3F, demonstrating that the unique jumping mechanism of APOBEC3F abrogates the influence of sliding on mutagenesis. Overall, we demonstrate key differences in the impact of APOBEC3F- and APOBEC3G-induced mutagenesis on HIV-1 that supports a model in which both the processive DNA scanning mechanism and preferred deamination motif (APOBEC3F, 5'TTC; APOBEC3G 5'CCC) influences the mutagenic and gene inactivation potential of an APOBEC3 enzyme.

Citing Articles

Engineered deaminases as a key component of DNA and RNA editing tools.

Budzko L, Hoffa-Sobiech K, Jackowiak P, Figlerowicz M Mol Ther Nucleic Acids. 2023; 34:102062.

PMID: 38028200 PMC: 10661471. DOI: 10.1016/j.omtn.2023.102062.

Host cell restriction factors of equine infectious anemia virus.

Wang X, Zhang X, Ma W, Li J, Wang X Virol Sin. 2023; 38(4):485-496.

PMID: 37419416 PMC: 10436108. DOI: 10.1016/j.virs.2023.07.001.

Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.

Yousefi M, Annan Sudarsan A, Gaba A, Chelico L Viruses. 2023; 15(2).

PMID: 36851677 PMC: 9960753. DOI: 10.3390/v15020463.

Competition for DNA binding between the genome protector replication protein A and the genome modifying APOBEC3 single-stranded DNA deaminases.

Wong L, Sami A, Chelico L Nucleic Acids Res. 2022; 50(21):12039-12057.

PMID: 36444883 PMC: 9757055. DOI: 10.1093/nar/gkac1121.

Small-Angle X-ray Scattering (SAXS) Measurements of APOBEC3G Provide Structural Basis for Binding of Single-Stranded DNA and Processivity.

Barzak F, Ryan T, Mohammadzadeh N, Harjes S, Kvach M, Kurup H Viruses. 2022; 14(9).

PMID: 36146779 PMC: 9505750. DOI: 10.3390/v14091974.

References

Pak V, Heidecker G, Pathak V, Derse D . The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J Virol. 2011; 85(17):8538-47. PMC: 3165795. DOI: 10.1128/JVI.02645-10. View

Stanford N, Szczelkun M, Marko J, Halford S . One- and three-dimensional pathways for proteins to reach specific DNA sites. EMBO J. 2000; 19(23):6546-57. PMC: 305861. DOI: 10.1093/emboj/19.23.6546. View

Sheehy A, Gaddis N, Malim M . The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med. 2003; 9(11):1404-7. DOI: 10.1038/nm945. View

Wiegand H, Doehle B, Bogerd H, Cullen B . A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 2004; 23(12):2451-8. PMC: 423288. DOI: 10.1038/sj.emboj.7600246. View

Albin J, Harris R . Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med. 2010; 12:e4. PMC: 2860793. DOI: 10.1017/S1462399409001343. View

Hache G, Shindo K, Albin J, Harris R . Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol. 2008; 18(11):819-24. PMC: 2491687. DOI: 10.1016/j.cub.2008.04.073. View

Bransteitter R, Prochnow C, Chen X . The current structural and functional understanding of APOBEC deaminases. Cell Mol Life Sci. 2009; 66(19):3137-47. PMC: 11115857. DOI: 10.1007/s00018-009-0070-y. View

Love R, Xu H, Chelico L . Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A. J Biol Chem. 2012; 287(36):30812-22. PMC: 3436324. DOI: 10.1074/jbc.M112.393181. View

Shlyakhtenko L, Lushnikov A, Miyagi A, Li M, Harris R, Lyubchenko Y . Atomic force microscopy studies of APOBEC3G oligomerization and dynamics. J Struct Biol. 2013; 184(2):217-25. PMC: 3844295. DOI: 10.1016/j.jsb.2013.09.008. View

10.

Koning F, Goujon C, Bauby H, Malim M . Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J Virol. 2011; 85(24):13448-52. PMC: 3233168. DOI: 10.1128/JVI.00775-11. View

11.

Harjes E, Gross P, Chen K, Lu Y, Shindo K, Nowarski R . An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol. 2009; 389(5):819-32. PMC: 2700007. DOI: 10.1016/j.jmb.2009.04.031. View

12.

Berger G, Durand S, Fargier G, Nguyen X, Cordeil S, Bouaziz S . APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog. 2011; 7(9):e1002221. PMC: 3178557. DOI: 10.1371/journal.ppat.1002221. View

13.

Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S . Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol. 2004; 11(5):435-42. DOI: 10.1038/nsmb758. View

14.

Furukawa A, Nagata T, Matsugami A, Habu Y, Sugiyama R, Hayashi F . Structure and real-time monitoring of the enzymatic reaction of APOBEC3G which is involved in anti-HIV activity. Nucleic Acids Symp Ser (Oxf). 2009; (53):87-8. DOI: 10.1093/nass/nrp044. View

15.

Gao F, Robertson D, Morrison S, Hui H, Craig S, Decker J . The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol. 1996; 70(10):7013-29. PMC: 190752. DOI: 10.1128/JVI.70.10.7013-7029.1996. View

16.

Sheehy A, Gaddis N, Choi J, Malim M . Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646-50. DOI: 10.1038/nature00939. View

17.

Stopak K, de Noronha C, Yonemoto W, Greene W . HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell. 2003; 12(3):591-601. DOI: 10.1016/s1097-2765(03)00353-8. View

18.

Belanger K, Savoie M, Gerpe M, Couture J, Langlois M . Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res. 2013; 41(15):7438-52. PMC: 3753645. DOI: 10.1093/nar/gkt527. View

19.

Harris R, Bishop K, Sheehy A, Craig H, Petersen-Mahrt S, Watt I . DNA deamination mediates innate immunity to retroviral infection. Cell. 2003; 113(6):803-9. DOI: 10.1016/s0092-8674(03)00423-9. View

20.

Nowarski R, Britan-Rosich E, Shiloach T, Kotler M . Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol. 2008; 15(10):1059-66. DOI: 10.1038/nsmb.1495. View